Perioperative use of etoricoxib reduces pain and opioid side-effects after total abdominal hysterectomy: a double-blind, randomized, placebo-controlled phase III study
Eugene R. Viscusi(Thomas Jefferson University), Paul M. Peloso(Genoscience Pharma (France)), Sean Curtis(University of North Carolina at Chapel Hill), Henrik Kehlet(Copenhagen University Hospital), Arnold R. Gammaitoni(Merck & Co., Inc., Rahway, NJ, USA (United States)), Dimitris A. Papanicolaou(Novartis (Switzerland)), Leslie Morgan(Merck & Co., Inc., Rahway, NJ, USA (United States)), Narinder Rawal(Örebro University), Anish Mehta(Merck & Co., Inc., Rahway, NJ, USA (United States)), Tara L. Frenkl(Merck & Co., Inc., Rahway, NJ, USA (United States)), Amy T. Ko(Merck & Co., Inc., Rahway, NJ, USA (United States)), Craig T. Hartrick(Beaumont Hospital, Royal Oak)
Cited by 26
Related Papers
Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Acute Pain Management From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists
|Regional Anesthesia & Pain Medicine|2018|583
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
|Annals of Oncology|2019|484
A systematic review and consensus definitions for standardised end-points in perioperative medicine: pulmonary complications
|British Journal of Anaesthesia|2018|432